MEN2A is associated with a classic tumor triad: in 90% percent of mutations with MEN2A, medullary thyroid carcinoma occurs; in 50%, adrenal PGL occurs; and in 20–30% parathyroid hyperplasia occurs. This evidence concerns the gene RET and neoplasm.